ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts. Investo ...

Supernus Pharmaceuticals (SUPN) closed the last trading session at $31.48, gaining 10.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $40.50 indicates a 28.7% upside potential. The average comprises four short-term price targets ranging from a low of $38 to a high of $43, with a standard deviation of $2.08. While the lowest estimate indicates an increase of 20.7% from the curren ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $168.3 million, up from $135.5 million in the same quarter last year, representing a significant increase [11] - Net product sales increased to $162.5 million, driven by growth products Qelbree and GOCOVRI [11] - GAAP net earnings for Q2 2024 were $19.9 million or $0.36 per diluted share, compared to a net loss of $831,000 or $0.02 loss per diluted share in the same quarter last year [12] - Adjusted operating earnings on a non-GAAP basis were $45.5 million, compared to $10 million in the same quarter last year, indicating a substantial increase [12][15] - For the first six months of 2024, total revenues were $312 million, up from $289.3 million in the same period last year [14] Business Line Data and Key Metrics Changes - Qelbree saw a 26% growth in prescriptions and a 92% increase in net sales, reaching $59 million in Q2 2024 [5][6] - GOCOVRI's net sales increased to $32 million, reflecting a 10% increase over the same period in 2023 [7] - Oxtellar XR net sales were $30 million, up from $24 million in the same quarter last year, while Trokendi XR sales decreased by 12% to $17 million [7] - Combined net sales of Trokendi XR and Oxtellar XR are expected to be in the range of $135 million to $145 million for 2024 [8] Market Data and Key Metrics Changes - The ADHD market grew by 8% year-to-date in 2024 compared to 3% in 2023, indicating a recovery in the overall market [25] - Adult prescriptions for Qelbree accounted for approximately 32% of total prescriptions, with a 26% growth in the adult patient population [6][34] Company Strategy and Development Direction - The company is focused on advancing its product pipeline, including SPN-817 for treatment-resistant seizures and SPN-820 for depression [5][10] - The company plans to initiate a Phase 1 study of SPN-443 for ADHD and other CNS disorders, indicating ongoing commitment to pipeline development [10] - The company is actively seeking strategic opportunities for growth and leadership in the CNS market [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resubmission of SPN-830, noting a lower number of issues compared to the previous submission [19] - The company anticipates strong performance in the back-to-school season, which is critical for Qelbree's growth [32] - Management raised its financial guidance for total revenue for 2024 to a range of $600 million to $625 million, reflecting optimism about continued growth [16] Other Important Information - The company reported approximately $347.2 million in cash and marketable securities as of June 30, 2024, up from $271.5 million at the end of 2021, indicating strong financial health [15] - The company has generated approximately $200 million in cash from operations in the past 18 months, providing significant financial flexibility for potential M&A opportunities [15] Q&A Session Summary Question: Confidence in SPN-830 approval - Management expressed confidence in the resubmission of SPN-830, noting fewer issues compared to the previous submission and a pre-resubmission meeting with the FDA [19] Question: SPN-817 Phase 2a data - Management expects to report additional patients completing the maintenance period for SPN-817, with a good number anticipated for the full results [20][21] Question: Expectations for Calgary during back-to-school season - Management expects robust growth in prescriptions for Calgary, with a recovery in the ADHD market compared to the previous year [25][26] Question: Adult population growth and pricing - Management indicated that adult prescriptions are driving improved pricing, with a significant difference in average prescription costs between adult and pediatric patients [36] Question: Future penetration in adult population - Management expects the adult population's share of prescriptions to increase over time, with ongoing efforts to enhance market penetration [39]

For the quarter ended June 2024, Supernus Pharmaceuticals (SUPN) reported revenue of $168.33 million, up 24.2% over the same period last year. EPS came in at $0.36, compared to -$0.02 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $148.8 million, representing a surprise of +13.12%. The company delivered an EPS surprise of -2.70%, with the consensus EPS estimate being $0.37. While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.70%. A quarter ago, it was expected that this drugmaker would post earnings of $0.39 per share when it actually produced break-even earnings, delivering a surprise of -100%. Over the last four quarters, th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Rockville MD | --- | |----------| | | | | | | | Employer | | No.) | | | | | Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. ...

Exhibit 99.1 Supernus Announces Second Quarter 2024 Financial Results ® • Net sales of Qelbree increased 92% in the second quarter of 2024, compared to the same period in 2023. ◦ $59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively. • Net sales of GOCOVRI increased 10% in the second quarter of 2024, compared to the same period in 2023. ® ◦ $31.7 million and $58.3 million of net sales in the second quarter and first six months of 2024, respectively. • ...

Net sales of Qelbree® increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively. Net sales of GOCOVRI® increased 10% in the second quarter of 2024, compared to the same period in 2023. $31.7 million and $58.3 million of net sales in the second quarter and first six months of 2024, respectively. Total revenues were $168.3 million in the second quarter of 2024, an increase of ...

ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD). Supernus believes it has addressed the U.S. Food and Drug Administrat ...

ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD). Supernus believes it has addressed the U.S. Food and Drug Administrat ...